<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Over-expression of transcription factor nuclear factor-κB (NF-κB) in the <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual tumor</z:e> after the treatment is often observed at the later period of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> radiotherapy, results in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> radioresistance and poor treatment outcome </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we combined <z:chebi fb="0" ids="50924">sorafenib</z:chebi>, a multikinase inhibitor, with ionizing radiation to evaluate the therapeutic effect, and to elucidate the possible mechanism responsible for the radiosensitization of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> on a human HT29/tk-luc colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> in vitro and in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>Clonogenic survival and cell cycle analysis were used to evaluate the cytotoxicity of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> in vitro </plain></SENT>
<SENT sid="3" pm="."><plain>The combination effect and the role of NF-κB in therapeutic efficacy with respects in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell invasion were studied with HT29/tk-luc <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing animal model </plain></SENT>
<SENT sid="4" pm="."><plain>The expression of NF-κB and its downstream-related proteins were assayed with electrophoretic mobility shift assay (EMSA) and Western blot </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="50924">Sorafenib</z:chebi> combined with radiation shows the synergistic cytotoxicity on HT29/tk-luc cells and increased <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>Both EMSA and Western blot show that the NF-κB activity induced by radiation is significantly suppressed by <z:chebi fb="0" ids="50924">sorafenib</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Combination of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> and radiation shows the maximum <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibition as compared to that of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> alone or radiation alone in vivo (P&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, the effect of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> combined with radiation for the treatment of human colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> is synergistic </plain></SENT>
<SENT sid="9" pm="."><plain>The mechanism of synergism is through the inhibition of radiation-induced NF-κB expression and its regulated downstream gene products </plain></SENT>
</text></document>